Status:
COMPLETED
A Non-Interventional Pilot Study Assessing Whether Lysyl Oxidase-like 2 (LOXL2) is Present in Subjects With Scleroderma
Lead Sponsor:
Gilead Sciences
Conditions:
Limited Scleroderma
Diffuse Scleroderma
Eligibility:
All Genders
18+ years
Brief Summary
To treat patients with scleroderma by blocking the expression of LOXL2. The investigators first need to confirm (through observation) that LOXL2 is overexpressed in disease.
Detailed Description
Scleroderma is a chronic skin-hardening disease. There are two types of scleroderma. The first type is called limited cutaneous scleroderma, where disrupted blood flow causes skin discoloration and so...
Eligibility Criteria
Inclusion
- Over 18 years of age
- Documented diagnosis of scleroderma
- Willing and able to provide written informed consent
Exclusion
- Use of experimental therapies within 28 days prior to Screening.
- Aspirin use \> 81 mg daily within 1 week prior to Screening.
- Any lab abnormality or concurrent medical condition that, in the opinion of the investigator would make the patient ineligible for the study
Key Trial Info
Start Date :
April 1 2013
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 1 2014
Estimated Enrollment :
29 Patients enrolled
Trial Details
Trial ID
NCT01881529
Start Date
April 1 2013
End Date
March 1 2014
Last Update
April 17 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
St Vincent's Centre for Applied Medical Research
Darlinghurst, New South Wales, Australia, 2010